Reserpine treatment activates AMP activated protein kinase (AMPK).
10.20307/nps.2017.23.3.157
- Author:
Rackhyun PARK
1
;
Kang Il LEE
;
Hyunju KIM
;
Minsu JANG
;
Thi Kim Quy HA
;
Won Keun OH
;
Junsoo PARK
Author Information
1. Division of Biological Science and Technology, Yonsei University, Wonju 26493, Republic of Korea. junsoo@yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Reserpine;
AMPK;
FOXO3a;
PC12;
MCF-7
- MeSH:
AMP-Activated Protein Kinases*;
Animals;
Cell Death;
Hypertension;
MCF-7 Cells;
PC12 Cells;
Phosphorylation;
Reserpine*;
Threonine
- From:Natural Product Sciences
2017;23(3):157-161
- CountryRepublic of Korea
- Language:English
-
Abstract:
Reserpine is a well-known medicine for the treatment of hypertension, however the role of reserpine in cell signaling is not fully understood. Here, we report that reserpine treatment induces the phosphorylation of AMP activated protein kinase (AMPK) at threonine 172 (T172) in PC12 cells. Phosphorylation of AMPK T172 is regulated by upstream signaling molecules, and the increase of phospho-T172 indicates that AMPK is activated. When we examined the FOXO3a dependent transcription by using the FHRE-Luc reporter assay, reserpine treatment repressed the FHRE-Luc reporter activity in a dose dependent manner. Finally, we showed that reserpine treatment induced the phosphorylation of AMPK as well as cell death in MCF-7 cells. These results suggest that AMPK is a potential cellular target of reserpine.
